Categories: BioTechCenterDevelopmentMedtechProductUniversityWebsite
VarmX develops a modified factor Xa as a reversal agent for anti-coagulants.
Investors 4
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.05.2023 | - | $32.17M | - |
| 09.07.2020 | Series B | $36.12M | - |
| 02.07.2018 | Series A | $8.73M | - |
Mentions in press and media 8
| Date | Title | Description |
| 16.09.2025 | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
Tue, Sep 16, 2025 14:00 CET Report this content
VarmX is developing a bypass agent to restore coagulat... |
| 25.05.2023 | VarmX Raises €30M in Series B2 Financing | VarmX, a Leiden, Netherlands-based biotech company focusing on the development of approaches for the reversal of anticoagulation, raised €30M in Series B2 funding.
The round was led by Sound Bioventures whilst the European Innovation Counci... |
| 25.05.2023 | VarmX raises €30M to develop therapeutic proteins that restore hemostasis in bleeding patients | Leiden-based VarmX, a biotech company developing “innovative” approaches for the reversal of anticoagulation (also known as blood thinners), announced on Thursday that it has secured an additional €30M in a Series B2 round of funding.
The D... |
| 18.10.2021 | EU Commission selects 65 startups to receive €363M funding to support innovations; meet the 8 Dutch startups selected | The European Commission has announced that it has selected 65 innovative startups and SMEs to be funded through the European Innovation Council (EIC) Fund.
Eight of these companies are based out of the Netherlands.
Please leave this field e... |
| 09.07.2020 | VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants | 08/07/2020
Press release
VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS.
• Financing co-led by Ysios Capital and ... |
| 02.07.2018 | VarmX Closes € 7.5M Series A Financing Round | VarmX, a Leiden, The Netherlands-based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, closed a Series A financing round of € 7.5m.
The round was led by the existing shareholder BioGenerat... |
| 27.06.2017 | VarmX Closes Seed Financing Round | VarmX, a Leiden, Netherlands-based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, closed its seed financing round.
Backers included BioGeneration Ventures (BGV) and InnovationQuarter.
The... |
| - | VarmX | “Home | Varmx” |
Reviews 0
